News | February 26, 2010

Anti-Platelet Therapy Subject of ACC Lunch Session

February 26, 2010 – The field of cardiovascular therapy is being transformed continuously due to the emergence of new anti-platelet agents possessing unique properties. During ACC 2010, the session “Bleeding: Why Does It Matter?” will discuss these therapies from 12:30-1:30 p.m. Saturday, March 13.

Long-term combination anti-platelet therapy after coronary intervention has been recommended as a means to reduce clinical adverse events. Educational courses on this discipline are needed in order to enhance comprehension of clinical risks and benefits of these new agents, particularly in relation to bleeding.

Lunch will be served between noon and 12:30 p.m. The session is being held in room A305 of the Georgia World Congress Center, 285 Andrew Young International Blvd., NW, Atlanta.

The event is sponsored by the Cardiovascular Research Foundation and supported by an independent medical education grant from the Bristol-Myers Squibb/Sanofi Pharmaceuticals partnership. This event is not part of the official ACC Annual Scientific Session and/or the ACC’s Innovation in Intervention: i2.

To register online visit:

Related Content

Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals | October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
News | Pharmaceuticals | October 04, 2017
October 4, 2017 — MyoKardia Inc.
News | Pharmaceuticals | September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Merck Announces Results of REVEAL Outcomes Study of Anacetrapib
News | Pharmaceuticals | September 11, 2017
Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and...
Statins Associated With Improved Heart Structure and Function
News | Pharmaceuticals | May 26, 2017
Statins are associated with improved heart structure and function, according to research presented at EuroCMR 2017, May...
Feature | Pharmaceuticals | May 16, 2017
May 16, 2017 – Results of a groundbreaking clinical trial demonstrate the effectiveness of a novel, fast-acting nasal
Prescribing Patterns Change Following Direct Marketing Restrictions
News | Pharmaceuticals | May 05, 2017
A study of how policies restricting pharmaceutical promotion to physicians affect medication prescribing found...
EBBINGHAUS study, evolocumab, repatha, statin therapy, cognitive issues, ACC.17 study
News | Pharmaceuticals | April 03, 2017
There is no evidence that adding a new cholesterol-lowering drug to treatment with a statin causes memory loss or other...
Overlay Init